Cidofovir: Difference between revisions

Jump to navigation Jump to search
← Older editNewer edit →
VisualWikitext
Gerald Chi (talk | contribs)
CMEAdmin, Bureaucrats, bureaucrats, editnews, exportpages, interwiki, nocaptcha, nukepages, smwadministrator, Administrators, Widget editors
17,702 edits
m Changed protection level for "Cidofovir" ([Edit=Allow only autoconfirmed users] (expires 15:54, 7 January 2014 (UTC)) [Move=Allow only autoconfirmed users] (expires 15:54, 7 January 2014 (UTC)))
ShiSheng (talk | contribs)
nocaptcha
8,707 edits
No edit summary
Line 1: Line 1:
{{drugbox
__NOTOC__
| IUPAC_name = [1-(4-amino-2-oxo-pyrimidin-1-yl)- 3-hydroxy-propan-2-yl] oxymethylphosphonic acid
{{Cidofovir}}
| image = Cidofovir.png
{{CMG}}
| width = 163
 
| CAS_number = 113852-37-2
==Overview==
| ATC_prefix = J05
| ATC_suffix = AB12
| ATC_supplemental =
| PubChem = 60613
| DrugBank = APRD00148
| C=8 | H=14 | N=3 | O=6 | P=1
| molecular_weight = 279.187 g/mol
| melting_point = 260
| specific_rotation = -97.3
| bioavailability = complete
| protein_bound = 6%
| metabolism =
| excretion = renal
| elimination_half-life = 2.4 to 3.2 hours
| pregnancy_US = C
| legal_status =
| routes_of_administration = intravenous
}}
'''Cidofovir''' is an injectable [[antiviral]] medication for the treatment of [[cytomegalovirus]] (CMV) [[retinitis]] in patients with [[AIDS]]. It suppresses CMV replication by selective inhibition of viral DNA synthesis.
'''Cidofovir''' is an injectable [[antiviral]] medication for the treatment of [[cytomegalovirus]] (CMV) [[retinitis]] in patients with [[AIDS]]. It suppresses CMV replication by selective inhibition of viral DNA synthesis.


Cidofovir demonstrated a statistically significant effect in delaying the progression of CMV retinitis lesions in newly diagnosed patients, as well as in previously treated patients who had failed other therapies. Maintenance therapy with cidofovir involves an infusion only once every two weeks, making it a convenient treatment option. Because dosing is relatively infrequent, a permanent catheter is not necessary for infusions. The major side effect of cidofovir is that it can be [[nephrotoxic]].
Cidofovir demonstrated a statistically significant effect in delaying the progression of CMV retinitis lesions in newly diagnosed patients, as well as in previously treated patients who had failed other therapies. Maintenance therapy with cidofovir involves an infusion only once every two weeks, making it a convenient treatment option. Because dosing is relatively infrequent, a permanent catheter is not necessary for infusions. The major side effect of cidofovir is that it can be [[nephrotoxic]].


*Cidofovir has also shown efficacy in the treatment of [[acyclovir]] resistant [[herpes]]
==Category==
 
Antiviral
*Cidofovir has also been investigated as a treatment for [[progressive multifocal leukoencephalopathy]], but [[as of 2005]] studies are inconclusive.


*Cidofovir might have anti-[[smallpox]] efficacy and might be used on a limited basis in the event of a [[bioterror]] incident involving smallpox cases.
==US Brand Names==
CIDOFOVIR<sup>®</sup>


*Cidofovir shows anti-[[BK virus]] activity in a subgroup of transplant patients.
==FDA Package Insert==


*Cidofovir is being investigated as a complementary intralesional therapy during laryngo- and bronchoscopic excision of papillomatosis caused by HPV.
'''  [[Cidofovir description|Description]]'''
'''| [[Cidofovir clinical pharmacology|Clinical Pharmacology]]'''
'''| [[Cidofovir microbiology|Microbiology]]'''
'''| [[Cidofovir indications and usage|Indications and Usage]]'''
'''| [[Cidofovir contraindications|Contraindications]]'''
'''| [[Cidofovir warnings and precautions|Warnings and Precautions]]'''
'''| [[Cidofovir adverse reactions|Adverse Reactions]]'''
'''| [[Cidofovir drug interactions|Drug Interactions]]'''
'''| [[Cidofovir overdosage|Overdosage]]'''
'''| [[Cidofovir clinical studies|Clinical Studies]]'''
'''| [[Cidofovir dosage and administration|Dosage and Administration]]'''
'''| [[Cidofovir how supplied|How Supplied]]'''
'''| [[Cidofovir labels and packages|Labels and Packages]]'''


Cidofovir was developed by [[Gilead Sciences]] and is marketed with the brand name '''Vistide''' by Gilead in the USA, and by [[Pfizer]] elsewhere.
==Mechanism of Action==


{{Antivirals}}
==References==
[[Category:Gilead Sciences]]
[[Category:Antivirals]]


{{antimicrobial-stub}}
{{Reflist|2}}


[[fr:Cidofovir]]
[[Category:Antibiotics]]
[[th:ไซโดโฟเวียร์]]
[[Category:Wikinfect]]
{{WikiDoc Help Menu}}

Revision as of 21:12, 2 January 2014

Cidofovir
VISTIDE® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Overdosage
Clinical Studies
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Cidofovir is an injectable antiviral medication for the treatment of cytomegalovirus (CMV) retinitis in patients with AIDS. It suppresses CMV replication by selective inhibition of viral DNA synthesis.

Cidofovir demonstrated a statistically significant effect in delaying the progression of CMV retinitis lesions in newly diagnosed patients, as well as in previously treated patients who had failed other therapies. Maintenance therapy with cidofovir involves an infusion only once every two weeks, making it a convenient treatment option. Because dosing is relatively infrequent, a permanent catheter is not necessary for infusions. The major side effect of cidofovir is that it can be nephrotoxic.

Category

Antiviral

US Brand Names

CIDOFOVIR®

FDA Package Insert

Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages

Mechanism of Action

References

Retrieved from "https://www.wikidoc.org/index.php?title=Cidofovir&oldid=923335"